Welcome to our dedicated page for Coya Therapeutics news (Ticker: COYA), a resource for investors and traders seeking the latest updates and insights on Coya Therapeutics stock.
Coya Therapeutics, Inc. (NASDAQ: COYA) is a clinical-stage biotechnology company headquartered in Houston, Texas, with news flow centered on its regulatory T cell (Treg)–focused pipeline for neurodegenerative and inflammation-driven diseases. Company updates frequently highlight progress with COYA 302, an investigational proprietary biologic combination of low-dose interleukin-2 (LD IL-2) and CTLA-4 Ig, and COYA 303, an investigational combination of LD IL-2 and a GLP-1 receptor agonist.
Investors following COYA news can expect regular coverage of clinical trial milestones, including the Phase 2 ALSTARS Trial of COYA 302 in amyotrophic lateral sclerosis (ALS). Coya has announced key events such as FDA acceptance of its IND for COYA 302 in ALS, Health Canada’s acceptance of a Clinical Trial Application, initiation and dosing of patients in the ALSTARS Trial, and milestone payments received under its Development and License Agreement with Dr. Reddy’s Laboratories Ltd.
News items also describe regulatory developments for frontotemporal dementia (FTD), including FDA acceptance of an IND for COYA 302 in FTD and results from an investigator-initiated open-label study of low-dose IL-2 and CTLA4-Ig in FTD patients. Additional releases cover preclinical data for COYA 303 in an in vivo model of systemic and neurologic inflammation, corporate financing activities such as an upsized public offering of common stock, and quarterly financial results and corporate updates.
This COYA news page aggregates these disclosures so readers can review clinical, regulatory, scientific, and financing announcements in one place. For those tracking Treg-based approaches to ALS, FTD, Alzheimer’s disease, and related conditions, the news stream provides direct access to Coya’s reported data, trial status updates, and key corporate events over time.
Coya Therapeutics (NASDAQ: COYA) announced the acceptance of a peer-reviewed manuscript in Frontiers in Neurology. The study, titled 'A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis,' highlights the halting of ALS progression at six months. The therapy also showed reduced inflammation and oxidative stress, and enhanced Regulatory T cell (Treg) function. This data was previously presented at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference and the 2024 Society of Neuroimmune Pharmacology Conference. Dr. Fred Grossman, Coya's Chief Medical Officer, sees this as significant validation for their approach.
Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company focused on enhancing regulatory T cell function, announced its inclusion in the MSCI USA Micro Cap Index, effective May 31, 2024. The Index, which tracks over 1,100 micro cap stocks with an average market cap of $122 million as of April 30, 2024, influences many microcap ETFs. CEO Howard Berman highlighted this inclusion as evidence of Coya's strategic focus and commitment to developing therapies for neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's. Coya anticipates several key milestones throughout 2024 that could significantly impact its trajectory.
Coya Therapeutics has completed a Phase 2 study on low-dose Interleukin-2 (LD IL-2) for mild-to-moderate Alzheimer's disease (AD). The double-blind, placebo-controlled study involved 38 patients over 30 weeks and was funded by the Gates Foundation and Alzheimer’s Association. The study aims to assess the safety, tolerability, and biological activity of LD IL-2. Preliminary data showed significant improvements in cognitive function and Treg cell activity in an earlier open-label study. Topline results are expected in summer 2024. The study was led by Drs. Stanley Appel and Alireza Faridar at Houston Methodist Hospital.
Coya Therapeutics has announced a $5 million investment from the Alzheimer's Drug Discovery Foundation (ADDF) to support the development of COYA 302 for Frontotemporal Dementia (FTD). The investment involves the purchase of 603,136 shares at $8.29 per share. COYA 302, a combination drug, aims to suppress neuroinflammation by targeting multiple inflammatory pathways. This move aligns with ADDF's strategy of combination therapies for treating complex neurodegenerative diseases.
The funds will help advance COYA 302 into a Phase 2 trial for FTD. The ADDF's support reinforces the potential of combination therapies in combating diseases like Alzheimer's and FTD, which lack effective treatment options currently.
Coya Therapeutics, Inc. (Nasdaq: COYA) has expanded its clinical pipeline with COYA 302 for neurodegenerative diseases such as ALS, Parkinson's, FTD, and AD. The company announced successful meetings with the FDA, expanded patents, and presented data on immune system contributions. Coya's CEO highlighted the potential of COYA 302 in treating complex immune pathways and neurodegenerative diseases. Financially, Coya had $36.0 million in cash and cash equivalents as of March 31, 2024, with increased R&D and administrative expenses leading to a net loss of $5.1 million.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.